Biocept (BIOC) to Present Liquid Biopsy Platform Data at ESMO 2016

September 29, 2016 8:05 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Biocept, Inc. (Nasdaq: BIOC) announces that clinical results featuring its liquid biopsy platform will be presented at the 2016 European Society For Medical Oncology (ESMO) Annual Congress, taking place October 7-11 in Copenhagen, Denmark. Study results highlighting the concordance and clinical utility of detecting actionable biomarkers in patients with advanced non-small cell lung cancer (NSCLC) will be presented by Lourdes Barrera, Ph.D., Diagnostics Manager, AstraZeneca Oncology BU, Mexico. An abstract for the presentation can be found at:

Presentation Details:

Title: Clinical evaluation of the utility of a liquid biopsy (circulating tumoral cells and ctDNA) to determine the mutational profile (EGFR, KRAS, ALK, ROS1 and BRAF) in advanced NSCLC patients Date and Time: Sunday, October 9, 2016, 4:30 p.m. CEST (Central European Summer Time) Basic Science and Translational Research; Poster Discussion Session: Berlin Room, Central Hall

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News

Add Your Comment